Zidovudine after occupational exposure to the human immunodeficiency virus.

Use of zidovudine following occupational exposure to human immunodeficiency virus.

Zidovudine after occupational exposure to HIV.








Zidovudine for prophylaxis of human immunodeficiency virus infection after accidental exposure.

Prophylaxis with zidovudine (AZT) after exposure to human immunodeficiency virus: a brief discussion of the issues for emergency physicians.

Zidovudine in the treatment of human immunodeficiency virus disease.

Continued zidovudine or didanosine for human immunodeficiency virus infection.

Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy.

Quantitation of human immunodeficiency virus (HIV) with respect to disease stage and zidovudine (AZT) therapy.

Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.

Failure of zidovudine prophylaxis after exposure to HIV-I.

Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.

Human occupational and nonoccupational exposure to fibers.

Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine.

Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.

Suggest Documents

Use of zidovudine following occupational exposure to human immunodeficiency virus.

Zidovudine after occupational exposure to HIV.

Zidovudine after occupational exposure to HIV.

Zidovudine after occupational exposure to HIV.

Zidovudine after occupational exposure to HIV.

Zidovudine after occupational exposure to HIV.

Zidovudine after occupational exposure to HIV.

Zidovudine after occupational exposure to HIV.

Zidovudine after occupational exposure to HIV.

Zidovudine for prophylaxis of human immunodeficiency virus infection after accidental exposure.

Prophylaxis with zidovudine (AZT) after exposure to human immunodeficiency virus: a brief discussion of the issues for emergency physicians.

Zidovudine in the treatment of human immunodeficiency virus disease.

Continued zidovudine or didanosine for human immunodeficiency virus infection.

Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy.

Quantitation of human immunodeficiency virus (HIV) with respect to disease stage and zidovudine (AZT) therapy.

Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.

Failure of zidovudine prophylaxis after exposure to HIV-I.

Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.

Human occupational and nonoccupational exposure to fibers.

Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine.

Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.

Zidovudine after occupational exposure to the human immunodeficiency virus.

Recommend Documents

Follow Us